Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19

7/15 N/A

Kavanagh et al., Med. Hypotheses, doi:10.1016/j.mehy.2020.110110 (Peer Reviewed)
Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19

Source PDF Share Tweet

Proposal to use an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatment of asthma. Authors advocate for early treatment or prophylaxis of COVID-19, using HCQ as an inhaled aerosol, to deliver the drug directly to the lungs at a lower dose than that required for oral systemic delivery.

Kavanagh et al., 7/15/2020, peer-reviewed, 9 authors.

All 344 studies Meta Analysis

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit